Home › Funds › Opaleye Management Inc. › TRVI
Opaleye Management Inc. position in TRVI
TREVI THERAPEUTICS INC · Health Care
Opaleye Management Inc. reported holding 310,000 shares of TRVI (TREVI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$5.8M, representing 0.52% of its reported portfolio and ranking #33 among its reported holdings. Opaleye Management Inc. has disclosed TRVI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Opaleye Management Inc.'s TRVI position evolved
Opaleye Management Inc. first disclosed a stake in TRVI in Q3 2023 at 1,705,900 shares (US$3.7M). The position peaked in Q4 2024 at 2,317,500 shares, worth US$9.5M. Across 12 filings, Opaleye Management Inc. increased the stake 2 time(s), trimmed it 6 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 310,000 shares valued at US$5.8M — a reduction of -35,100 shares quarter over quarter.. Notable position changes include a 49% increase in Q4 2023 (shares rose 157% over the following quarter), a 66% trim in Q1 2025 (shares fell 13% over the following quarter), a 51% trim in Q2 2025 (shares rose 67% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.71M | $3.72M | New |
| Q4 2023 | 2.54M | $3.40M | Add |
| Q1 2024 | 2.65M | $9.13M | Add |
| Q2 2024 | 2.65M | $7.88M | Hold |
| Q3 2024 | 2.57M | $8.58M | Reduce |
| Q4 2024 | 2.32M | $9.55M | Reduce |
| Q1 2025 | 795.00K | $5.00M | Reduce |
| Q2 2025 | 390.00K | $2.13M | Reduce |
| Q3 2025 | 390.00K | $3.57M | Hold |
| Q4 2025 | 345.10K | $4.32M | Reduce |
| Q1 2026 | 345.10K | $4.12M | Hold |
| Q2 2026 | 310.00K | $5.78M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRVI and 13F data
TRVI (TREVI THERAPEUTICS INC) is a Health Care company. 64 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vivo Capital, LLC (US$95.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRVI
- NEA Management Company, LLC 13.22M sh · $246.59M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.94M sh · $185.37M · Q2 2026
- Vivo Capital, LLC 5.09M sh · $95.02M · Q2 2026
- Vestal Point Capital, LP 3.10M sh · $57.81M · Q2 2026
- MPM BioImpact LLC 3.07M sh · $57.32M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 2.66M sh · $49.61M · Q2 2026
- Artia Global Partners LP 2.21M sh · $41.23M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 2.14M sh · $40.00M · Q2 2026
- First Light Asset Management, LLC 2.10M sh · $39.11M · Q2 2026
- Logos Global Management LP 1.88M sh · $35.06M · Q2 2026
- Affinity Asset Advisors, LLC 1.80M sh · $33.57M · Q2 2026
- Siren, L.L.C. 1.79M sh · $33.33M · Q2 2026
More on Opaleye Management Inc.
FAQ
How long has Opaleye Management Inc. held TRVI?
Opaleye Management Inc. has disclosed TRVI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Opaleye Management Inc.'s current position in TRVI?
As of Q2 2026, Opaleye Management Inc. holds 310.00K shares of TRVI (TREVI THERAPEUTICS INC), valued at $5.78M, representing 0.52% of its reported portfolio and ranking #33.
Has Opaleye Management Inc. been buying or selling TRVI?
In the latest 13F filing (Q2 2026), Opaleye Management Inc. reduced its position in TRVI. The position peaked in Q4 2024 at 2.32M shares.
Which other funds hold TRVI?
Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.